Posted by Michael Wonder on 22 Dec 2022
Mirati announces adagrasib (Krazati) receives breakthrough therapy designation from FDA for patients with advanced, KRAS mutated colorectal cancer
21 December 2022 - The US FDA has granted breakthrough therapy designation for adagrasib (Krazati) in combination with cetuximab in patients with KRASG12C mutated advanced colorectal cancer whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.
A Phase 3 trial evaluating adagrasib in combination with cetuximab in patients with KRASG12C mutated colorectal cancer in the second-line setting compared with standard chemotherapy (KRYSTAL-10) is currently on-going.
